Odalasvir

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Odalasvir
Odalasvir structure.svg
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
Formula C60H72N8O6
Molar mass 1001.26368 g/mol
3D model (JSmol)

Odalasvir (INN,[1] previously known as ACH-3102)[2][3] is an investigational new drug in development for the treatment of hepatitis C.[4] It is an NS5A inhibitor.[5] The NS5A protein serves multiple functions at various stages of the viral life cycle, including viral replication. NS5A also plays a role in the development of interferon-resistance, a common cause of treatment failure.[6][7][8] It is under development by Achillion Pharmaceuticals.

See also[edit]

References[edit]

  1. ^ "International Nonproprietary Names for Pharmaceutical Substances (INN). RECOMMENDED International Nonproprietary Names: List 73" (PDF). who.int. World Health Organization. p. 38. Retrieved 5 December 2015. 
  2. ^ "Achillion Has Discovered and Developed a Comprehensive Portfolio of Antivirals for the Treatment of Hepatitis C". Achillion Pharmaceuticals. Retrieved 15 November 2015. 
  3. ^ Odalasvir at ChemIDplus
  4. ^ Walker, Tracey (December 2015). "Watch list 2016: top therapeutic areas: experts say you should follow these 6 therapeutic areas". Managed Healthcare Executive: 47. Retrieved March 12, 2016. 
  5. ^ Nakamoto S, Kanda T, Wu S, Shirasawa H, Yokosuka O. Hepatitis C virus NS5A inhibitors and drug resistance mutations. World J Gastroenterol. 2014 Mar 21;20(11):2902-12. doi: 10.3748/wjg.v20.i11.2902. PMID 24659881
  6. ^ ACH-3102 resources. Achillion pharmaceuticals. Winter 2011. Accessed May 2012.
  7. ^ Achillion gets FDA incentives for hepatitis C drug. Associated Press. 15 May 2012.
  8. ^ Levin, Jules. Preclinical characteristics of ACH-3102. Conference report. European Association for the Study of the Liver, 47th Annual Meeting. April 18th - 22nd 2012. Barcelona, Spain